This brand-new, industry-led, three-day summit is the only event entirely dedicated to the strategic application of Model-Informed Drug Development (MIDD). It brings together senior leaders in pharmacometrics, clinical pharmacology, PK/PD, and modeling to explore how MIDD is transforming drug development across therapeutic areas including oncology, CNS, CVRM, RNA, and immunology.

Through case studies, regulator-led sessions, and cross-functional discussions, you’ll uncover practical strategies to bridge the communication gap between modelers and biologists, decode the ICH M15 draft to future-proof regulatory submissions, and see how pioneers are using MIDD to optimize dose selection, reduce patient exposure, and accelerate timelines.

This is your opportunity to benchmark against industry leaders, exchange real-world experiences, and leave with a clear, actionable roadmap to maximize the ROI of MIDD in your own programs.